Elanco Animal Health Inc (ELAN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Elanco Animal Health’s revenue went from $2.9B in fiscal 2016 to $4.7B in fiscal 2025, growth of about 5.5% a year.
Net income in fiscal 2025 was -$232M, a net margin of -4.9%; the best year in this period was 2024 with $338M.
Over the twelve months to September 30, 2026, revenue was $5.1B and net income -$147M.
Free cash flow was $284M in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count rose 69% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B | $4.7B | $4.4B | $4.4B | $4.4B | $4.8B | $3.3B | $3.1B | $3.1B | $2.9B | $2.9B |
| Gross profit | $2.9B | $2.6B | $2.4B | $2.5B | $2.5B | $2.6B | $1.6B | $1.6B | $1.5B | $1.4B | $1.5B |
| Operating income | -$92M | -$224M | $488M | -$1.2B | -$72M | -$571M | -$675M | $78M | $114M | -$233M | -$22M |
| Net income | -$147M | -$232M | $338M | -$1.2B | -$78M | -$483M | -$574M | $68M | $86M | -$311M | -$48M |
| EPS (diluted) | $-0.30 | $-0.47 | $0.68 | $-2.50 | $-0.16 | $-0.99 | $-1.30 | $0.18 | $0.28 | $-1.06 | $-0.16 |
| R&D | $381M | $368M | $344M | $327M | $321M | $369M | $329M | $270M | $247M | $252M | $266M |
| Revenue growth | — | +6.2% | +0.5% | +0.1% | −7.4% | +45.6% | +6.6% | +0.1% | +6.2% | −0.8% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $614M | $560M | $541M | $271M | $452M | $483M | -$41M | $224M | $487M | $174M | $156M |
| Capital spending | -$206M | -$276M | -$147M | -$140M | -$171M | -$159M | -$135M | -$140M | -$134M | -$99M | -$110M |
| Free cash flow | $408M | $284M | $394M | $131M | $281M | $324M | -$176M | $84M | $353M | $75M | $46M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $77M | $68M | $55M | $46M | $59M | $66M | $47M | $49M | $26M | $25M | $20M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $545M | $468M | $352M | $345M | $638M | $495M | $334M | $475M | $323M | $259M |
| Debt | — | $4.1B | $4.4B | $5.9B | $6.0B | $6.5B | $6.3B | $2.4B | $2.5B | $0 | — |
| Equity | — | $6.5B | $6.1B | $6.2B | $7.3B | $7.5B | $8.5B | $5.5B | $5.2B | $7.8B | $7.0B |
| Total assets | — | $13.4B | $12.6B | $14.4B | $15.5B | $16.5B | $17.7B | $9.0B | $9.0B | $8.9B | — |
| Shares (diluted) | 506M | 496M | 497M | 492M | 488M | 487M | 441M | 370M | 314M | 293M | 293M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 56.2% | 55.0% | 54.9% | 56.3% | 56.6% | 55.2% | 49.1% | 52.1% | 48.7% | 48.3% | 51.6% |
| Operating margin | -1.8% | -4.8% | 11.0% | -27.1% | -1.6% | -12.0% | -20.6% | 2.5% | 3.7% | -8.1% | -0.8% |
| Net margin | -2.9% | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | -17.5% | 2.2% | 2.8% | -10.8% | -1.6% |
| FCF margin | 7.9% | 6.0% | 8.9% | 3.0% | 6.4% | 6.8% | -5.4% | 2.7% | 11.5% | 2.6% | 1.6% |
| ROIC | — | -1.7% | 3.2% | -7.8% | -0.4% | -3.5% | -3.9% | 0.9% | 1.1% | -2.4% | -0.2% |
| ROE | — | -3.5% | 5.5% | -19.8% | -1.1% | -6.4% | -6.8% | 1.2% | 1.7% | -4.0% | -0.7% |
Frequently asked questions
What is Elanco Animal Health’s annual revenue?
$4.7B in fiscal 2025 and $5.1B over the twelve months to September 30, 2026.
How much profit does Elanco Animal Health make?
Net income was -$232M in fiscal 2025 (net margin -4.9%).
Is Elanco Animal Health’s revenue growing?
Yes: revenue rose 6.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.